PEOPLE - UK private equity and venture capital firm 3I makes appointment:
This article was originally published in Clinica
As part of its aim to increase its investment in healthcare, London-based UK private equity and venture capital firm 3i has appointed Peter Chambre as an industrialist-in-residence. Mr Chambre has 13 years' experience of leading healthcare companies, including Bespak (CEO), the Cambridge Antibody Technology Group (CEO) and Celera Genomics Group (COO). As part of 3i's industrialist-in-residence programme, Mr Chambre will identify, evaluate and complete deals in the healthcare sector, and provide significant levels of leadership assistance to businesses that are backed by 3i. Mr Chambre is currently a non-executive director of BTG (life sciences, UK) and Spectris (precision engineering, UK).
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.